Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.70 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.69 |
| ▸ | FERMT2 | Q96AC1 | 4/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | HTR1A | P08908 | 1/20 | 0.59 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.59 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.59 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.59 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.57 |
| ▸ | CDK1 | P06493 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23340476 | 0.86 | NR4A2 (0.54) | CCR1NR4A2FERMT2CYP1A2 | |
| SCHEMBL23883137 | 0.86 | NR4A2 (0.54) | CCR1NR4A2FERMT2CYP1A2 | |
| SCHEMBL15481296 | 0.85 | CCR1 (0.97) | CCR1NR4A2FERMT2CYP1A2HTR1A | |
| SCHEMBL17527057 | 0.85 | CCR1 (0.97) | CCR1NR4A2FERMT2CYP1A2HTR1A | |
| SCHEMBL12643220 | 0.85 | CCR1 (0.97) | CCR1NR4A2FERMT2CYP1A2HTR1A | |
| SCHEMBL23340236 | 0.85 | CCR1 (0.72) | CCR1NR4A2FERMT2CYP1A2HRH3 | |
| SCHEMBL20434214 | 0.83 | CCR1 (0.78) | CCR1NR4A2FERMT2CYP1A2HTR1A | |
| SCHEMBL3647594 | 0.82 | NR4A2 (1.00) | CCR1NR4A2FERMT2CYP1A2HRH3 | |
| SCHEMBL23883151 | 0.82 | CCR1 (0.84) | CCR1NR4A2FERMT2CYP1A2HRH3 | |
| SCHEMBL16547269 | 0.82 | CCR1 (0.84) | CCR1NR4A2FERMT2CYP1A2HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230022696-A1 | SMALL MOLECULE INHIBITORS OF AUTOPHAGY AND HISTONE DEACTYLASES AND USES THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2023-01-26 | — | — | US | disclosed |
| WO-2021087077-A1 | SMALL MOLECULE INHIBITORS OF AUTOPHAGY AND HISTONE DEACTYLASES AND USES THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2021-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230022696-A1 | SMALL MOLECULE INHIBITORS OF AUTOPHAGY AND HISTONE DEACTYLASES AND USES THEREOF | HDAC5, HDAC4, HDAC7 | CCR1 4704/4885NR4A2 932/4885FERMT2 4750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.